NCT03426631View on ClinicalTrials.gov

DAW1033B2 in Obstructive Sleep Apnea

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

October 1, 2019

Study Completion Date

January 20, 2020

Conditions
Obstructive Sleep Apnea (OSA)
Interventions
DRUG

Placebo oral capsule

Placebo capsule 30 minutes before sleep

DRUG

DAW1033B2 oral capsule

DAW1033B2 capsule 30 minutes before sleep

Trial Locations (1)

02115

Sleep Disorders Research Program Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT03426631 - DAW1033B2 in Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter